TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo

• Main Authors: Jun-Hee Park, Sang Woo Kim, Min-Ji Cha, Nara Yoon, Chang Youn Lee, Jiyun Lee, Hyang-Hee Seo, Sunhye Shin, Jung-Won Choi, Seahyoung Lee, Soyeon Lim, Ki-Chul Hwang
• Format: Article
• Language: English
• Published: Nature Publishing Group 2018-04-01
• Series: Experimental and Molecular Medicine
• Online Access: https://doi.org/10.1038/s12276-018-0052-y

Atherosclerosis: Potential therapy based on prospective cancer drug Drug undergoing trials as a cancer treatment shows promise in tackling the narrowing of blood vessels in other diseases. The thickening of arterial walls and consequent restriction of blood flow, typical of conditions like atherosclerosis, increases the risk of heart attacks and strokes. Soyeon Lim and Ki-Chul Hwang at the Catholic Kwandong University, South Korea, and co-workers have investigated the efficacy of a prospective cancer drug called TAK-733 against atherosclerosis both in cell culture and in trials on rat models of the disease. The team hypothesized that TAK-733’s anti-cancer effects could prove useful in treating other conditions. They demonstrated that TAK-733 successfully blocked the proliferation and migration of vascular smooth muscle cells, the overexpression of which is a dominant factor in the development of atherosclerosis.